Search

U.S. FDA Approves Once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes

Transition to renewable energy signals a broader commitment to environmental sustainability

Building lasting partnerships for a better future

Working with the University of Georgia, we’ve co-created a sustainability training initiative that benefits people, animals and the planet.

Meet our Team

Meet Our Team

NVSS: The Future Vets & Scientists | Boehringer Ingelheim US

Click here to read more on the annual National Veterinary Scholars Symposium, celebrating future veterinarians and scientists across the USA.

Leticia develops product medical strategies

Leticia develops product medical strategies at Boehringer Ingelheim. For more talent insights, visit our Careers Page.

U.S. FDA Grants Breakthrough Therapy Designation for Spesolimab for the Prevention of Flares in Adults with Generalized Pustular Psoriasis (GPP)

U.S. FDA approves Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) tablets for adults with type 2 diabetes

Adopting shelter pets: Employees make a difference at work and home

FDA Approves OFEV® (nintedanib) to Treat IPF | BI US

Read more about the FDA approval of Boehringer Ingelheim's OFEV, the first Kinase Inhibitor used to treat idiopathic pulmonary fibrosis (IPF).

USDA & BI Expand Research Opportunities | Boehringer Ingelheim US

Find out more about how veterinary students will work with USDA scientists in researching emerging diseases related to both animal and public health.

Pre-Employment

Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline

Boehringer Ingelheim today announced a strong acceleration of its pipeline in 2023, as pivotal trials in key research areas progressed as planned.

Sustainable Development - Our Commitment

Our Commitment

Schizophrenia in real life: Stories of resilience and hope

Discover the reality of life with schizophrenia through the stories of four people who are breaking down the stigma of living with a serious mental illness.

We nurture innovative ideas

At Boehringer Ingelheim, we know to really make a difference we need to innovate. That’s why we embrace and invest in innovation every single day.

Where to meet us | Animal Health Boehringer Ingelheim US

Find out where to meet the BD&L team virtually or in person at the next conference or event. Submit your opportunity to our BD&L team here.

Animal Health

Companion Animals, Horse Pets and Equines

Boehringer Ingelheim Launches Observational Study on Management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate mesylate)

Boehringer Ingelheim Presents First Head-to-Head Matched Population Comparison

Netherlands

Boehringer Ingelheim Launches Groundbreaking Initiative “Cuida tu Don” with Entertainer “Don Francisco” Aimed at Hispanics with Type 2 Diabetes

Information Technology

Embracing Differences: Our journey to diversity, equity, and inclusion

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

U.S. FDA Approves Once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes

Transition to renewable energy signals a broader commitment to environmental sustainability

Building lasting partnerships for a better future

Meet our Team

NVSS: The Future Vets & Scientists | Boehringer Ingelheim US

Leticia develops product medical strategies

U.S. FDA Grants Breakthrough Therapy Designation for Spesolimab for the Prevention of Flares in Adults with Generalized Pustular Psoriasis (GPP)

U.S. FDA approves Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) tablets for adults with type 2 diabetes

Adopting shelter pets: Employees make a difference at work and home

FDA Approves OFEV® (nintedanib) to Treat IPF | BI US

USDA & BI Expand Research Opportunities | Boehringer Ingelheim US

Pre-Employment

Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline

Sustainable Development - Our Commitment

Schizophrenia in real life: Stories of resilience and hope

We nurture innovative ideas

Where to meet us | Animal Health Boehringer Ingelheim US

Animal Health

Boehringer Ingelheim Launches Observational Study on Management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate mesylate)

Boehringer Ingelheim Presents First Head-to-Head Matched Population Comparison

Netherlands

Boehringer Ingelheim Launches Groundbreaking Initiative “Cuida tu Don” with Entertainer “Don Francisco” Aimed at Hispanics with Type 2 Diabetes

Information Technology

Embracing Differences: Our journey to diversity, equity, and inclusion

Contact Us